Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 2,490 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Arbutus Biopharma Corporation | ABUS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.07 | 2.05% | 3.48 | 04:48:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.41 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 11 | 2,490 | - | 1.69 - 3.43 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:33:39 | 8 | $ 3.48 | USD |
Arbutus Biopharma Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 612.07M | 179.49M | - | 18.14M | -72.85M | -0.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Arbutus Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABUS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.82 | 3.43 | 2.81 | 3.20 | 1,127,521 | 0.66 | 23.40% |
| 1 Month | 2.70 | 3.43 | 2.63 | 2.94 | 742,308 | 0.78 | 28.89% |
| 3 Months | 2.87 | 3.43 | 2.30 | 2.89 | 1,176,965 | 0.61 | 21.25% |
| 6 Months | 1.85 | 3.43 | 1.79 | 2.70 | 1,067,334 | 1.63 | 88.11% |
| 1 Year | 2.62 | 3.43 | 1.69 | 2.47 | 845,668 | 0.86 | 32.82% |
| 3 Years | 2.75 | 6.50 | 1.69 | 3.50 | 1,923,259 | 0.73 | 26.55% |
| 5 Years | 2.09 | 9.00 | 0.81 | 3.66 | 2,067,908 | 1.39 | 66.51% |
Arbutus Biopharma Description
| Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
